Research programme: oligonucleotide therapeutics for pain - OliPass
Latest Information Update: 12 Jul 2016
At a glance
- Originator OliPass
- Class Analgesics; Oligonucleotides
- Mechanism of Action Nav1.7-voltage-gated-sodium-channel-inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neuropathic pain
Most Recent Events
- 12 Jul 2016 Preclinical trials in Neuropathic pain in South Korea (unspecified route)